We found that genetically matched cells (where scientists control specific gene changes) accurately predict patient responses, while standard cancer cell collections often show different patterns.
📊 How do we know if a cancer drug will work? It starts with choosing the right lab test. Newly published Garvan research compared different lab testing methods for PARP inhibitors – important drugs for people with cancers caused by BRCA mutations
Last month we announced that Garvan was awarded the inaugural Collaborative Research Accelerator (CRA) grant from the National Breast Cancer Foundation (NBCF) for its AllClear program, led by Garvan’s Associate Professor Christine Chaffer and Professor Peter Croucher.
🧬 A recent Garvan-led study (GENIE) is recruiting Australian children and adults to help improve the early detection of genetic conditions that affect the immune system.
Congratulations to Dr Hasindu Gamaarachchi, awarded the 2025 #EurekaPrizes for Outstanding Early Career Researcher! He is developing computational methods to dramatically cut time and power needed to analyse genomic sequencing data, with huge ramifications for medical research.
Did you know? Garvan and Yale University researchers paired up to develop a new AI tool that could be integrated into cancer diagnostics to better inform treatment.
AAnet, led by A/Prof Christine Chaffer, Prof Sarah Kummerfeld & A/Prof Smita Krishnaswamy, maps tumour cells into 5 distinct groups, each with vastly different biology.
Tumours aren’t just one type of cell — they’re a mix, each responding to treatment differently. But today, most cancer therapies treat them all the same.
Garvan Institute & Yale researchers have created AAnet, a powerful AI tool that studies individual cells within cancer tumours, opening the door to more targeted therapies. #AI#CancerResearch
Today our lab head Prof Marina Pajic, along with Prof Anthony Joshua and PurpleOurWorld’s Daniel Goulburn OAM delivered an inspiring public seminar today at @garvaninstitute.bsky.social on how we are working to improve outcomes for patients with #PancreaticCancer.
Congratulations to Garvan researcher Shanon Ranjit, who last week won the Early-Stage Innovation Forum pitch as part of the AusMedtech conference. Shanon is part of the team leading Garvan's Genomics Platform.
Sydney researchers are recruiting for a study aimed at improving diagnosis, treatment and support for an estimated two million people who live with rare genetic diseases in Australia alone.
Why does the arm you choose for a vaccine matter? 🩹
New research from Garvan and the Kirby Institute shows that receiving a booster in the same arm as the initial dose can lead to a quicker, stronger immune response.
Watch Garvan researchers and collaborators share insights on transforming inflammatory bowel disease diagnosis and treatment approaches in this informative session.
